Cameron Turtle Biography and Net Worth

CEO of Spyre Therapeutics

Cameron Turtle, D.Phil., is Chief Executive Officer. He is an experienced leader in building, financing, and shaping biopharma organizations from preclinical development to late-stage clinical trials and commercialization. Previously, he served as Venture Partner at Foresite Labs, as well as Chief Strategy Officer of BridgeBio Pharma. Prior to BridgeBio Pharma, Inc., Dr. Turtle was the Chief Business Officer of Eidos Therapeutics, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for heart failure. Prior to joining Eidos, he was a consultant at McKinsey & Company, where he worked with pharmaceutical and medical device companies on topics including M&A, growth strategy, clinical trial strategy, and sales force optimization. Dr. Turtle also serves on the board of directors of Oruka Therapeutics, Inc. Dr. Turtle received his B.S. with honors in bioengineering from the University of Washington and his D.Phil. in cardiovascular medicine from the University of Oxford, St. John’s College. He is the recipient of several awards, including a Rhodes Scholarship, a Goldwater Scholarship, Forbes 30 Under 30, and San Francisco Business Times 40 Under 40.

What is Cameron Turtle's net worth?: The estimated net worth of Cameron Turtle is at least $22.98 million as of December 1st, 2025. Mr. Turtle owns 686,907 shares of Spyre Therapeutics stock worth more than $22,977,039 as of December 8th. This net worth estimate does not reflect any other assets that Mr. Turtle may own. Additionally, Mr. Turtle receives a salary of $674,170.00 as CEO at Spyre Therapeutics. Learn More about Cameron Turtle's net worth.
How old is Cameron Turtle?: Mr. Turtle is currently 34 years old. There are 2 older executives and no younger executives at Spyre Therapeutics. Learn More on Cameron Turtle's age.
What is Cameron Turtle's salary?: As the CEO of Spyre Therapeutics, Inc., Mr. Turtle earns $674,170.00 per year. Learn More on Cameron Turtle's salary.
How do I contact Cameron Turtle?: The corporate mailing address for Mr. Turtle and other Spyre Therapeutics executives is 805 Las Cimas Parkway, Suite 100, Austin, TX 78746, United States. Spyre Therapeutics can also be reached via phone at 512-942-2935 and via email at [email protected]. Learn More on Cameron Turtle's contact information.
Has Cameron Turtle been buying or selling shares of Spyre Therapeutics?: Over the course of the past ninety days, Cameron Turtle has sold $1,485,150.00 of Spyre Therapeutics stock. Most recently, Cameron Turtle sold 15,000 shares of the business's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $29.02, for a transaction totalling $435,300.00. Following the completion of the sale, the chief executive officer now directly owns 686,907 shares of the company's stock, valued at $19,934,041.14. Learn More on Cameron Turtle's trading history.
Who are Spyre Therapeutics' active insiders?: Spyre Therapeutics' insider roster includes Jeffrey Albers (Director), Scott Burrows (CFO), and Cameron Turtle (CEO). Learn More on Spyre Therapeutics' active insiders.
Are insiders buying or selling shares of Spyre Therapeutics?: In the last twelve months, insiders at the sold shares 3 times. They sold a total of 78,428 shares worth more than $1,784,789.28. The most recent insider tranaction occured on December, 1st when CEO Cameron Turtle sold 15,000 shares worth more than $435,300.00. Insiders at Spyre Therapeutics own 6.2% of the company. Learn More about insider trades at Spyre Therapeutics.
Information on this page was last updated on 12/1/2025.

Cameron Turtle Insider Trading History at Spyre Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/1/2025	Sell	15,000	$29.02	$435,300.00	686,907
11/3/2025	Sell	45,000	$23.33	$1,049,850.00	701,907

Cameron Turtle Buying and Selling Activity at Spyre Therapeutics

Spyre Therapeutics Company Overview

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Today's Range

Now: $33.45

$33.00

$34.06

50 Day Range

MA: $23.35

$15.89

$33.51

2 Week Range

Now: $33.45

$10.91

$34.54

Volume

548,159 shs

Average Volume

626,230 shs

Market Capitalization

$2.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.13

Cameron Turtle Biography and Net Worth

What is Cameron Turtle's net worth?

How old is Cameron Turtle?

What is Cameron Turtle's salary?

How do I contact Cameron Turtle?

Has Cameron Turtle been buying or selling shares of Spyre Therapeutics?

Who are Spyre Therapeutics' active insiders?

Are insiders buying or selling shares of Spyre Therapeutics?